Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
4.36 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0.014 |
| Cost of Revenue
| 1.389 | 1.426 | 0.544 | 0.16 | 0.111 | 0 |
| Gross Profit
| -1.389 | -1.426 | -0.544 | -0.16 | -0.111 | 0.014 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 1 |
| Reseach & Development Expenses
| 189.59 | 172.734 | 175.601 | 84.901 | 38.386 | 18.921 |
| General & Administrative Expenses
| 59.398 | 54.553 | 40.941 | 33.886 | 8.459 | 4.876 |
| Selling & Marketing Expenses
| -1.389 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 62.962 | 54.553 | 40.941 | 33.886 | 8.459 | 4.876 |
| Other Expenses
| 45.568 | 0 | 0 | 0 | -0.016 | 0 |
| Operating Expenses
| 252.552 | 227.287 | 216.542 | 118.787 | 46.845 | 23.797 |
| Operating Income
| -253.941 | -227.287 | -216.542 | -118.787 | -46.845 | -23.783 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | -1,698.786 |
| Total Other Income Expenses Net
| -22.951 | 5.987 | 51.983 | 0.683 | 0.482 | 0.355 |
| Income Before Tax
| -276.892 | -221.3 | -164.559 | -118.104 | -46.363 | -23.428 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | -1,673.429 |
| Income Tax Expense
| -0.601 | -0.469 | -0.297 | 0.444 | 0.015 | 0.004 |
| Net Income
| -292.191 | -220.831 | -164.262 | -118.548 | -46.378 | -21.067 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | -1,504.786 |
| EPS
| -4.47 | -4.18 | -3.85 | -2.89 | -1.29 | -1.17 |
| EPS Diluted
| -4.47 | -4.18 | -3.85 | -2.89 | -1.29 | -1.17 |
| EBITDA
| -252.552 | -233.274 | -268.525 | -119.47 | -46.734 | -23.732 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | -1,695.143 |